Adir Et Compagnie

Albert Lenaers

Jean-Paul Vilaine

Gilbert Regnier

Claude Guillonneau

Jean-Pierre Iliou

Jean-Pierre Bidouard

Christine Breugnot

Charles E Malen

Jean-Michel Lacoste

Nicole Villeneuve

Yves Rolland

Catherine Thollon

Guy Lewin

Alain Lombet

J F Benaud De La Faverie

New substituted phenoxyisobutyric acids and esters that can be used as medicaments and correspond to the formula: ##STR1## wherein X, A, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and Z are as defined in the description. Those compounds and their physiologically tolerable salts can be used therapeutically.

Substituted phenoxyisobutyric acids and esters

Compounds of the general formula (I): ##STR1## in which R represents: a hydrogen atom, or a radical --OR' in which R' is as defined in the description.

3',5'-di-tert.-butyl-4'-hydroxy flavones

The compounds are substituted trimetazidine useful for the treatment of ischaemic pathologies and peripheral vascular pathology. A compound disclosed is 4-(2,3,4-trimethoxybenzyl)-1-[3-(4-hydroxy-2,3,5-trimethylphenoxy)propyl]p iperazine.

Trimetazidine compounds

The invention relates to the compounds of formula (I): ##STR1## in which R represents higher alkyl, 1-(higher alkyl)lower cycloalkyl-1-yl or higher alkenyl comprising one or more double bonds, and either

Acylaminophenol compounds

The compounds are 8-substituted 1-oxa-2-oxo-3,8-diazaspiro [4.5]decanes useful for the treatment of dyslipidaemiae, atherosclerosis and pathologies in which membrane lipid peroxidation plays an initiating and/or aggravating role. A compound disclosed is (R,S)-8-[3(3,5-di-tert.-butyl-4-hydroxyphenylthio)-2-hydroxypropyl]-1-oxa- 2oxo-3,8-diazaspiro [4.5]decane.

Spiro(4.5.)decane compounds

The compounds disclosed are 1-R'-4-RS-piperidines in which R' and R, which are different, may each represent: (1) (alkoxybenzyl)-alkyl or -alkenyl, or (2) (optionally-substituted chromanyl-, thiochromanyl-, chromenyl- or thiochromenyl)-alkyl or -alkenyl. The compounds are useful in the treatment of disorders associated with tissue ischaemia and of peripheral vascular disorders or in the treatment of disorders in which lipid peroxidation plays an initiating and/or aggravating role. A typical disclosed compound is: 4-(2,3,4-tirmethoxybenzylthio)-1-(3,5-di- tert-butyl-4-hydroxybenzyl)piperidine. ,3,4-trimethoxybenzylthio)-1-(3,5-di-tert-butyl-4-hydroxybenzyl)piperidine .

Growing community of inventors

Triel-sur-Seine, France

Albert Lenaers